Uveitis drugs in development, 2023
The Uveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Uveitis. Buy the report here.The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Uveitis and features dormant and discontinued products.GlobalData tracks 85 drugs in development for Uveitis by 77 companies/universities/institutes. The top development phase for Uveitis is preclinical with 51 drugs in that stage. The Uveitis pipeline has 81 drugs in development by companies and four by universities/ institutes. Some of the companies in the Uveitis pipeline products market are: Palatin Technologies, BioMarck Pharmaceuticals and Tarsier Pharma.The key targets in the Uveitis pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R), and Nuclear Factor Kappa B (NFKB).The key mechanisms of action in the Uveitis pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with 11 drugs in Pre-Registration. The Uveitis pipeline products include 11 routes of administration with the top ROA being Ophthalmic and 13 key molecule types in the Uveitis pipeline products market including Small Molecule, and Synthetic Peptide.Uveitis overviewUveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors include infection, autoimmune or inflammatory disorder, and history of eye injury. Treatment includes steroid eye drops, anti-inflammatories, antibiotics, or antiviral medication.For a complete picture of Uveitis's pipeline drug market, buy the report here.
GlobalData tracks 85 drugs in development for Uveitis by 77 companies/universities/institutes. The top development phase for Uveitis is preclinical, with 51 drugs in that stage.
What's Your Reaction?
